Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Ovarian Neoplasms × Indocyanine Green × Clear all

Phase

Status

Terminated 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Stomach Neoplasms 2 Endometrial Neoplasms 2 Thoracic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Lymphedema 1 Lung Neoplasms 1 Lung Diseases 1 Gastrointestinal Stromal Tumors 1 Gastrointestinal Diseases 1 Carcinoma, Hepatocellular 1

Interventions

Carboplatin 39 Paclitaxel 37 liposomal doxorubicin 22 pembrolizumab 16 Topotecan 15 Cyclophosphamide 15 Bevacizumab 14 Gemcitabine 13 Cisplatin 12 niraparib 9 fludarabine 7 Docetaxel 7 aldesleukin 6 1-dodecylpyridoxal 6 olaparib 5 fludarabine phosphate 5 Nivolumab 5 oregovomab 4 durvalumab 4 avelumab 4 Surgical Procedures, Operative 4 Peripheral Blood Stem Cell Transplantation 4 Melphalan 4 Interleukin-2 4 Etoposide 4 Doxorubicin 4 spartalizumab 3 sargramostim 3 rucaparib 3 pegfilgrastim 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04891185 2023-10-05

VIPIDO

Universitaire Ziekenhuizen KU Leuven

Phase 2 Terminated

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡